Abstract: Objective: To explore the serum levels change of Fractalkine, monocyte chemotactic protein-1(MCP-1) and interleukin-8(IL-8) in patients with coronary heart disease(CHD) and its significance. Methods: After coronary angiography, 48 stable angina patients, 56 unstable angina patients, 37 acute myocardial infarction(AMI) patients and 50 healthy people were divided into the SA, UA, AMI and control group, respectively. The serum levels of Fractalkine, MCP-1 and IL-8 in four groups were measured using enzyme-linked immunosorbent assay, and the severity of coronary artery disease was evaluated by Judkins method. Results: The serum levels of Fractalkine, MCP-1 and IL-8 in CHD patients were significantly higher than those in control group(P<0.01), and the serum levels of Fractalkine, MCP-1 and IL-8 in UA and AMI group were significantly higher than those in SA group(P<0.01). The serum levels of Fractalkine, MCP-1 and IL-8 in patients with double arteries and multiple arteries disease were significantly higher than those in patients with single artery disease(P<0.01). The serum levels of Fractalkine, MCP-1 and IL-8 in patients with severe stenosis and moderate stenosis were significantly higher than those in patients with mild stenosis(P<0.01). Conclusions: The CHD patient illness aggravates with the serum levels of Fractalkine, MCP-1 and IL-8 increasing, which can evaluate the severity and development of disease in CHD patients.